April 2020 Press releases
Bio-Gate AG: Screening test proves effectiveness of various MicroSilver BG™ products against viruses
-
- Tested products are already available on the market
- Additional new products with antiviral effects soon to be launched
- Bio-Gate products suitable for extending existing hygiene strategies
Nuremberg, April 15th 2020 – Bio-Gate AG (ISIN DE000BGAG981), one of the leading providers of innovative technologies and solutions for health and hygiene, has proven in a screening test in cooperation with a renowned and certified test laboratory in Germany, that MicroSilver BG™ and various products that contain MicroSilver BG™ are effective against enveloped viruses.
The family of enveloped viruses includes for example the current corona virus (SARS-Cov2), SARS (SARS-Cov), MERS (MERS-CoV) and influenza A. Hand sanitizers, hand gels, surface and textile sprays as well as shampoos were successfully tested. In addition, the tests demonstrated synergetic effects between MicroSilver BG™ and alcohol as well as with surfactants and soaps. All the products tested have been available on the market for some time.
MicroSilver BG™ is used in many healthcare and hygiene related products on the market including: skincare, wound care, medical devices (e.g. catheters, dental fillers); products for surfaces for consumer and industrial goods including: hospital chairs, sanitary equipment, door handles and frames, pipes, architectural wall paints, and coatings for equipment and airplanes. MicroSilver BG™ has been used for many years for its effective broad-spectrum antimicrobial properties and now the latest testing confirms that MicroSilver also has anti-viral effects.
MicroSilver BG™ is manufactured in Bio-Gate’s AG own facilities in Germany. MicroSilver BG™ is a pure silver powder additive with highly porous and micro-sized particles of silver. The large micro-particles remain on the surface of the skin / mucosa tissue. MicroSilver BG™ is a natural product certified according to COSMOS/Ecocert and the Natural Product Association (NPA)
Marc Lloret-Grau, CEO of Bio-Gate AG: “The Covid-19 pandemic and its rapid spread has shown how important the use of antiviral and antibacterial products has become in daily life. Doctors and virologists point out that, especially after the upcoming relaxation of corona measures, hygiene must be paid more attention to in order to keep new infections as low as possible. Bio-Gate has a variety of products to support the necessary hygienic requirements. The product range extends from antiviral and antibacterial solutions for the end user, through medical devices such as catheters, to supplements to the hygiene strategy in hygiene-sensitive areas such as hospitals and healthcare facilities. By proving the antiviral efficacy, we further round off our product portfolio with MicroSilver BG™”.
Please download the press release here as pdf.
Contact:
Contact:
Bio-Gate AG
Neumeyerstr. 28-34
90411 Nuremberg
Germany
www.bio-gate.de
North America:
Karl Richter
RFH BioTek Inc.
Phone: 416-407-6120
rfh@rfhBioTek.com
Toronto, Canada
Gerd Rückel
rikutis consulting
gr@rikutis.de
presse@bio-gate.de
Phone +49 (0) 6172 807309
Mobile +49 (0)152 34221966
About Bio-Gate AG:
Bio-Gate AG is a medical healthcare company and one of the world’s leading providers of innovative technologies for health and hygiene solutions. Bio-Gate specializes in developing materials and surfaces with antimicrobial properties that make living together safer and healthier – improving the well-being of every individual. Bio-Gate’s technology is used in medical applications such as the coating of implants, dental fillers, and wound care products. Bio-Gate’s products are also used in skincare and personal care applications, paints and coatings, and consumer and industrial hygiene products.
Disclaimer:
This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the “Shares”) may not be offered or sold in the United States or to or for the account or benefit of “U.S. persons” (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”)). The securities have already been sold.